These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19234707)

  • 41. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies.
    Di Stasi SM; Giannantoni A; Massoud R; Dolci S; Navarra P; Vespasiani G; Stephen RL
    Cancer Res; 1999 Oct; 59(19):4912-8. PubMed ID: 10519404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
    Rouprêt M; Neuzillet Y; Larré S; Pignot G; Coloby P; Rébillard X; Mongiat-Artus P; Chartier-Kastler E; Soulié M; Pfister C;
    Prog Urol; 2012 Nov; 22(15):920-31. PubMed ID: 23102014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC).
    Álvarez-Maestro M; Guerrero-Ramos F; Rodríguez-Faba O; Domínguez-Escrig JL; Fernández-Gómez JM
    Actas Urol Esp (Engl Ed); 2021 Mar; 45(2):93-102. PubMed ID: 33012593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
    Gözen AS; Umari P; Scheitlin W; Su FE; Akin Y; Rassweiler J
    Arch Ital Urol Androl; 2017 Jun; 89(2):102-105. PubMed ID: 28679178
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer.
    Malmström PU; Sylvester RJ; Crawford DE; Friedrich M; Krege S; Rintala E; Solsona E; Di Stasi SM; Witjes JA
    Eur Urol; 2009 Aug; 56(2):247-56. PubMed ID: 19409692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chemotherapy: Electromotive mitomycin in superficial bladder cancer.
    Oosterlinck W
    Nat Rev Clin Oncol; 2011 Sep; 8(11):633-4. PubMed ID: 21912417
    [No Abstract]   [Full Text] [Related]  

  • 48. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group.
    Witjes JA; v d Meijden AP; Collette L; Sylvester R; Debruyne FM; van Aubel A; Witjes WP
    Urology; 1998 Sep; 52(3):403-10. PubMed ID: 9730451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Second-line intravesical therapy. What is the present role of device-assisted therapy?].
    Racioppi M; D'Agostino D; Gianfrancesco LD; Bassi PF
    Urologia; 2013; 80 Suppl 21():37-41. PubMed ID: 23559138
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer.
    Batura D; Hashemzehi T; Colemeadow J
    Int Urol Nephrol; 2018 Jun; 50(6):1053-1059. PubMed ID: 29611146
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mitomycin C for the treatment of bladder cancer.
    Volpe A; Racioppi M; D'Agostino D; Cappa E; Filianoti A; Bassi PF
    Minerva Urol Nefrol; 2010 Jun; 62(2):133-44. PubMed ID: 20562793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
    Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reasons for intravesical instillation postponement during adjuvant treatment of non-muscle-invasive bladder cancer: A prospective study.
    Khan W; Zugail AS; Blanc E; Neuziller Y; Lebret T
    Prog Urol; 2020 Feb; 30(2):75-79. PubMed ID: 31953014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mitomycin C: new strategies to improve efficacy of a well-known therapy.
    Ragonese M; Racioppi M; Bassi PF; Di Gianfrancesco L; Lenci N; Filianoti A; Recupero SM
    Urologia; 2016 Oct; 83(Suppl 2):24-28. PubMed ID: 27647081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration.
    Pierconti F; Rossi ED; Straccia P; Fadda G; Larocca LM; Bassi PF; Sacco E; Schinzari G
    Cancer Cytopathol; 2018 Mar; 126(3):200-206. PubMed ID: 29360198
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.
    Mariappan P; Johnston A; Padovani L; Clark E; Trail M; Hamid S; Hollins G; Simpson H; Thomas BG; Hasan R; Bhatt J; Ahmad I; Nandwani GM; Mitchell IDC; Hendry D;
    Eur Urol; 2020 Oct; 78(4):520-530. PubMed ID: 32690321
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
    Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
    J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.
    Bahouth Z; Halachmi S; Moskovitz B; Nativ O
    Expert Rev Anticancer Ther; 2016; 16(2):189-98. PubMed ID: 26618756
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.
    Fankhauser CD; Teoh JY; Mostafid H
    Curr Opin Urol; 2020 May; 30(3):365-369. PubMed ID: 32141939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.